12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy.
Transgenic mice that expressed v-fos exclusively in the epidermis by means of a human keratin K1-based targeting vector (HK1.fos) developed preneoplastic epidermal hyperplasia and hyperkeratosis after long latency and an associated wound promotion stimulus. To assess the requirements for papilloma formation and malignant conversion and determine the sensitivity to a chemical promotion stimulus, HK1.fos mice were promoted with 12-O-tetradecanoylphorbol-13-acetate (TPA). HK1.fos mice were sensitive to TPA promotion but developed papillomas only after long latency (20-30 weeks of promotion) and in relatively few numbers per animal, suggesting the necessity of an additional genetic event prior to overt lesion formation. Consistent with this idea, at 60 weeks, on cessation of TPA promotion, these HK1.fos TPA-papillomas were found to be autonomous, TPA-independent tumors which persisted, grew larger, and converted to malignancy. Analysis of HK1.fos tumor RNA and DNA identified endogenous c-rasHa mutations at codons 12 and 61 in papillomas and carcinomas; however, no p53 tumor suppressor gene mutations were detected. These data indicate that epidermal expression of v-fos induces sensitivity to TPA promotion, but since additional genetic events, such as endogenous c-rasHa activation, appear to be required in tumorigenesis, v-fos may predominantly play a role in the mechanism of promotion to achieve papilloma autonomy and TPA independence. Furthermore, spontaneous malignant conversion in this model does not appear to involve mutations in the p53 tumor suppressor gene.
Greenhalgh
D A
DA
Department of Cell Biology and Dermatology, Baylor College of Medicine, Houston, Texas 77030, USA.
Wang
X J
XJ
Eckhardt
J N
JN
Roop
D R
DR
D000818:Animals; D001483:Base Sequence; D015415:Biomarkers; D002277:Carcinoma / Q000235:genetics / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D004273:DNA, Neoplasm; D004817:Epidermis / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D016762:Genes, fos; D016158:Genes, p53 / Q000235:genetics*; D011905:Genes, ras / Q000235:genetics*; D006965:Hyperplasia / Q000235:genetics / Q000473:pathology; D007633:Keratins / Q000032:analysis; D007642:Keratosis / Q000235:genetics / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009154:Mutation; D016761:Oncogene Proteins v-fos / Q000096:biosynthesis / Q000235:genetics; D010212:Papilloma / Q000235:genetics / Q000473:pathology; D012334:RNA, Neoplasm; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D018631:ras Proteins / Q000096:biosynthesis / Q000235:genetics
D015415:Biomarkers; D004273:DNA, Neoplasm; D016761:Oncogene Proteins v-fos; D012334:RNA, Neoplasm; D007633:Keratins; D018631:ras Proteins; D013755:Tetradecanoylphorbol Acetate